# VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia.

> **NCT07642453** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Hematology department of the 920th hospital** · enrollment: 110 (estimated)

## Conditions studied

- Acute Myeloid Leukemia (AML)

## Interventions

- **DRUG:** Venetoclax,Azacitidine,Arubicin,Cytarabine,G-CSF.

## Key facts

- **NCT ID:** NCT07642453
- **Lead sponsor:** Hematology department of the 920th hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2028-06-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07642453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07642453, "VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07642453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*